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Abstract
Patients with cutaneous T-cell lymphoma (CTCL) who have cutaneous tumors or folliculotropic disease involve-
ment typically have a poor prognosis. Analysis of the pivotal phase II trial of romidepsin for relapsed or refractory
CTCL showed that single-agent romidepsin induced a clinical response or stable disease in most patients with
cutaneous tumors and/or folliculotropic disease involvement, supporting its use in these patient populations.
Background: Tumor stage and folliculotropic mycosis fungoides are uncommon subtypes of cutaneous T-cell
lymphoma (CTCL) with an aggressive disease course. Romidepsin is a histone deacetylase inhibitor approved by the
US Food and Drug Administration for patients with CTCL who have received  1 previous systemic therapy. In the
present study, we examined the efﬁcacy and safety of romidepsin in patients from the pivotal, single-arm, open-label,
phase II study of relapsed or refractory CTCL with cutaneous tumors and/or folliculotropic disease involvement.
Materials and Methods: Patients with CTCL who had received  1 previous systemic therapy received romidepsin at
14 mg/m2 on days 1, 8, and 15 of 28-day cycles. Responses were determined by a composite endpoint (assessments
of the skin, blood, and lymph nodes). Patients with cutaneous tumors and/or folliculotropic disease involvement were
identiﬁed by review of diagnosis and histology reports. Results: The objective response rate to romidepsin was 45%
in patients with cutaneous tumors (n ¼ 20) and 60% in patients with folliculotropic disease involvement (n ¼ 10).
Conclusion: Romidepsin is active in subtypes of CTCL with less favorable outcomes, such as tumor stage and
folliculotropic mycosis fungoides.
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Cutaneous T-cell lymphomas (CTCLs) are a heterogeneous
group of non-Hodgkin lymphomas that are primarily indolent but
can be aggressive and are associated with a poor prognosis in late-
stage disease.1-3 CTCL is relatively rare, comprising z4% of
diagnosed cases of non-Hodgkin lymphoma in the United States.4
Although CTCL arises in the skin, it can progress to systemic
disease (lymph nodes, blood, viscera), resulting in signiﬁcantly
reduced survival.2,3,5 The most common forms of CTCL are
mycosis fungoides (MF) and Sézary syndrome (SS).1 The term1Yale Cancer Center, New Haven, CT
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http://dx.doi.org/10.1016/j.clml.2016.08.009CTCL is sometimes used interchangeably with MF/SS, but CTCL
encompasses various non-MF/SS subtypes.1,6,7 Many patients with
CTCL experience pruritus, visible manifestations of disease in the
skin, and infections, all of which can lead to signiﬁcant psycho-
logical burden, in addition to the physical burden of the disease.8,9
CTCL is staged according to the disease involvement in the skin,
lymph nodes, visceral organs, and blood.10 In early-stage disease,
skin involvement includes patches, plaques, and/or papules. Cuta-
neous tumors represent a distinct classiﬁcation and correspond to a
higher stage of disease (TNMB skin classiﬁcation T3, clinical stage
IIB) in the World Health Organization/European Organization for
Research and Treatment of Cancer staging system.10 The presence
of cutaneous tumors is also known to be an independent negative
prognostic factor for disease progression and survival and can be
accompanied by histologic large cell transformation.2,11
Folliculotropic mycosis fungoides (FMF) is characterized by
inﬁltration of the hair follicle by neoplastic T lymphocytes.12,13
FMF is associated with an aggressive disease course, a poor
response to treatment, an increased risk of disease progression, and
inferior overall survival.2,12 Patients with early-stage FMF typicallyClinical Lymphoma, Myeloma & Leukemia November 2016 - 637
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Romidepsin in Tumor Stage and Folliculotropic MFrespond less well to modalities such as ultraviolet light and topical
therapies, which tend to be efﬁcacious for early-patch and plaque-
stage disease. In many cases, patients with FMF respond similarly
to those with tumor-stage disease.12,14 Similar to other patients with
MF, those with FMF often have moderate to severe pruritus,14
which can signiﬁcantly affect patients’ quality of life.15
The epigenetic modiﬁer romidepsin is a structurally unique,
potent, bicyclic, class I selective histone deacetylase inhibitor16-18
approved by the US Food and Drug Administration for the treat-
ment of peripheral T-cell lymphoma (PTCL) in patients who have
received  1 previous therapy and for the treatment of CTCL in
patients who have received  1 previous systemic therapy.19
Approval for CTCL was based primarily on the results from a
pivotal phase II study of romidepsin administered at a dose of 14
mg/m2 on days 1, 8, and 15 of 28-day cycles to patients with
relapsed or refractory CTCL (N ¼ 96). The objective response rate
(ORR) was 34%, including 6% with a complete response, and the
median duration of response (DOR) was 15 months.20 Clinically
meaningful reductions in pruritus were noted in both objective
responders and clinical nonresponders.21
Despite the poor prognosis for patients with cutaneous tumors
and those with folliculotropic involvement, relatively few studies
have analyzed the clinical beneﬁt of approved systemic therapies.
We present an analysis of the efﬁcacy and safety of single-agent
romidepsin in patients with cutaneous tumors and/or folliculo-
tropic disease from the pivotal phase II trial.
Materials and Methods
Study Design
The details for the phase II, open-label, single-arm, international
study (GPI-04-0001; ClinicalTrials.gov identiﬁer, NCT00106431)
have been previously reported in detail.20 In brief, adult patients
with stage IB-IVA CTCL, including those with MF and SS, who
had received  1 previous systemic therapy were required to have
adequate organ function, Eastern Cooperative Oncology Group
performance status of 0 to 1, and no known signiﬁcant cardiac
abnormalities. The study was conducted in accordance with the
Guidelines of the World Medical Association Declaration of Hel-
sinki. The appropriately constituted institutional review board and/
or independent ethics committee of the participating institutions
reviewed and approved the study documentation. All the patients
provided written informed consent. Patients with cutaneous tumors
and/or folliculotropic involvement (diagnosed as FMF or CTCL
with a folliculotropic component) were identiﬁed by a review of the
diagnosis and histology reports. Romidepsin was administered at 14
mg/m2 as a 4-hour intravenous infusion on days 1, 8, and 15 of
28-day cycles for  6 cycles. Patients with stable disease (SD) or
response could continue treatment beyond 6 cycles at the discretion
of the patient and investigator. Concomitant antipruritic medica-
tions (eg, steroids, antihistamines) were not allowed to isolate the
beneﬁts of romidepsin treatment on pruritus. The response to
treatment was assessed at patient screening, at baseline, on day 1 of
each treatment cycle, and 30 days after the last cycle.
Efﬁcacy and Safety Assessments
The primary endpoint was the ORR, which was determined by a
rigorous composite assessment of response in the skin, lymph nodes,Clinical Lymphoma, Myeloma & Leukemia November 2016and blood. Key secondary endpoints included the DOR, time to
response (TTR), and time to progression. The reduction in pruritus
was measured using a patient-assessed 100-mm visual analog scale
(VAS; no itching [VAS ¼ 0] to unbearable itching [VAS ¼ 100]).
Patients with a baseline VAS score of 30 to 69 and 70 to 100 were
considered to have moderate and severe pruritus, respectively.
Treatment-emergent adverse events (AEs) were assessed at the
weekly treatment visits (days 1, 8, and 15 of each cycle) using the
National Cancer Institute Common Terminology Criteria for
Adverse Events grading system (version 3) and tabulated using the
Medical Dictionary for Regulatory Activities system organ class.
Statistical Analysis
All patients who had received  1 dose of romidepsin were
included in the efﬁcacy and safety analyses. Changes from baseline
over time in the VAS pruritus scores and TTR were assessed using
descriptive statistics. Time-to-event data were summarized using the
Kaplan-Meier method.
Results
Patient Baseline Demographics and Characteristics
Of 96 patients with CTCL, 20 had cutaneous tumors and 10 had
folliculotropic involvement (Table 1). Two patients had both
cutaneous tumors and folliculotropic involvement and were
included in both groups for the present analysis. Patients with
folliculotropic involvement were variably described in the histology
reports as having FMF/CTCL (n ¼ 3), follicular involvement
(n ¼ 4), folliculotropic element (n ¼ 1), secondary follicular in-
ﬂammatory changes (n ¼ 1), or involvement of the hair follicles
(n ¼ 1). The median age of the patients with cutaneous tumors
and/or folliculotropic involvement was comparable to that of the
overall study population, and most patients in both subpopulations
were male. Patients with cutaneous tumors and/or folliculotropic
involvement had undergone a similar number of previous skin-
directed therapies but a greater median number of previous
systemic therapies than that of the overall study population
(Table 1). One patient in the overall study had large cell trans-
formation (55-year-old woman, stage IIB at diagnosis) with cuta-
neous tumors and had previously received 4 topical and 4 systemic
therapies.
Efﬁcacy
Patients with cutaneous tumors and/or folliculotropic involve-
ment experienced a rapid response to romidepsin (median TTR, 1.9
and 2.1 months) with an ORR of 45% (9 of 20) and 60% (6 of 10),
respectively (Table 2). No signiﬁcant differences were observed in
the ORR between the patients with and those without cutaneous
tumors (P ¼ .443) or between the patients with and those without
folliculotropic involvement (P ¼ .075). Most patients with cuta-
neous tumors and/or folliculotropic involvement were able to
achieve SD or better (both 90%). One patient with cutaneous tu-
mors and large cell transformation had a best response of progressive
disease (PD). The DOR was not signiﬁcantly different statistically
for the patients with and without cutaneous tumors (P ¼ .748)
or for patients with and without folliculotropic involvement
(P ¼ .060). The longest DOR for the patients with folliculotropic
involvement ( 5.0 months) was in a patient who remained in
Table 1 Patient Demographics and Characteristics
Variable Overall (n [ 96) Cutaneous Tumors (n [ 20)a
Folliculotropic Involvement
(n [ 10)a
Male sex 59 (61) 14 (70) 7 (70)
Age (y)
Median 57 56 54
Range 21-89 21-77 36-83
Previous skin-directed therapies
Median 2 2 2
Range 0-6 1-5 1-5
Previous systemic therapies
Median 2 3 3.5
Range 1-8 1-7 1-7
Stage at diagnosis
IB 15 (16) 1 (5)b 1 (10)
IIA 13 (14) 0 (0) 2 (20)
IIB 21 (22) 9 (45) 1 (10)
III 23 (24) 4 (20) 2 (20)
IVA 24 (25) 6 (30) 4 (40)
Pruritus at baselinec
Moderate to severed 65 (69) 13 (68) 6 (67)
Severee 36 (38) 10 (53) 4 (44)
Data presented as n (%), unless otherwise noted.
aTwo patients had both cutaneous tumors and folliculotropic involvement and were included in both groups.
bThe patient was recorded as having cutaneous tumors and stage 1B disease at baseline.
cMeasured using 100-mm visual analog scale from no itching (score, 0) to unbearable itching (score, 100); 2 patients overall and 1 patient with both cutaneous tumors and folliculotropic involvement
did not have a baseline pruritus assessment.
dVisual analog scale score, 30 to 100 mm.
eVisual analog scale score, 70 to 100 mm.
Francine Foss et alcomplete response after completion of the planned 6 cycles of
treatment but chose to withdraw from the study (Figure 1). Patients
with cutaneous tumors and/or folliculotropic involvement experi-
enced marked reductions in pruritus from baseline (Table 2). In the
overall study population, 7 patients (2 with cutaneous tumors and 1
with folliculotropic involvement) had severe pruritus at baseline that
was completely resolved after treatment with romidepsin (VAS
score, 0 for  2 consecutive cycles). Patients with severe or
moderate-to-severe pruritus at baseline reported improvements
similar to that of the overall population. Increased pruritus was
reported in only 1 patient with cutaneous tumors and 1 patient with
folliculotropic involvement.
Safety
Treatment-emergent AEs in patients with cutaneous tumors
and/or folliculotropic involvement were generally comparable to
those of the overall study population (Figure 2). Patients with
folliculotropic involvement had a lower incidence of total AEs
(all grades and grades  3). Nausea was the most common AE
(56%; all drug-related) and was lowest in patients with folli-
culotropic involvement (40% vs. 55% of patients with cutaneous
tumors). Although grade  3 gastrointestinal AEs (vomiting,
diarrhea, nausea) were reported in the overall treatment popu-
lation, no grade  3 gastrointestinal AEs were reported in pa-
tients with cutaneous tumors and/or folliculotropic involvement.
Common (> 10%) hematologic AEs (thrombocytopenia,anemia) were more frequently reported in patients with cuta-
neous tumors. In contrast, patients with folliculotropic involve-
ment had the lowest incidence. Overall, the analysis of AEs (both
treatment-emergent and drug-related) in patients with cutaneous
tumors and/or folliculotropic involvement showed no new safety
signal. The patients in these 2 subgroups had AE proﬁles that
were generally comparable to those of the overall study
population.
Most withdrawals from treatment in both subgroups were
because of PD. Seven patients (35%) with cutaneous tumors and 3
(30%) with folliculotropic involvement (1 patient with both)
withdrew because of PD. No patients with folliculotropic involve-
ment withdrew from treatment because of an AE. One patient with
cutaneous tumors withdrew from treatment because of an AE
(fatigue) that was deemed drug-related. One patient with cutaneous
tumors died of cardiopulmonary failure, which was assessed by the
investigator as possibly related to the study drug. By independent
review, the death was assessed as caused by PD with attendant
cardiopulmonary insufﬁciency as the terminal event. No other
deaths occurred in either subgroup.
Discussion
Previous studies have shown that romidepsin is effective in
treating CTCL in all disease compartments (skin, lymph nodes, and
blood), in all disease stages (IB-IVA), and in populations with a
poor prognosis (SS) and greater risk of disease progression.2,20,22Clinical Lymphoma, Myeloma & Leukemia November 2016 - 639
Table 2 Outcomes With Romidepsin Treatment




Median 3.6 3.6 4.3
Range < 0.1-21.9 0.5-21.9 0.5-8.0
Best response
ORR 33 (34) 9 (45) 6 (60)
CR 6 (6) 2 (10) 1 (10)
SD 45 (47) 9 (45) 3 (30)
SD90 28 (29) 3 (15) 2 (20)
Time to response (mo)
Median 1.9 1.9 2.1
Range 0.9-4.8 1.9-4.7 1.0-4.8
DOR (mo)
Median 15.0 NR 3.6
Range <0.1 to 19.8þ 1.4 to 18.7þ 2.1 to 5.0þ
Best change in pruritus VAS scorec
Moderate to severe pruritus at
baselined
38  28 43  27 53  35
Severe pruritus at baselinee 49  28 45  29 60  42
Time to progression (mo)
Median 8.3 3.8 8.3
Range <0.1 to 21.7 0.9 to 21.7þ <0.1 to 8.3þ
Data presented as n (%) or mean  standard deviation, unless otherwise noted.
Abbreviations: CR ¼ complete response; DOR ¼ duration of response; NR ¼ not reached; ORR ¼ objective response rate; SD ¼ stable disease; SD90 ¼ stable disease for  90 days; VAS ¼ visual
analog scale.
aTwo patients had both cutaneous tumors and folliculotropic involvement and were included in both groups.
bResponse data missing for 1 patient with folliculotropic involvement.
cIncluded patients with baseline and postbaseline VAS data and a lack of confounding pruritus treatments necessary to calculate the change in VAS scores.
dVAS score, 30 to 100 mm.
eVAS score, 70 to 100 mm.
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640 -Additionally, reductions in pruritus were observed in each of these
subpopulations, demonstrating that romidepsin is effective at
providing clinical beneﬁt beyond the objective response in tradi-
tionally challenging CTCL subpopulations.22Figure 1 Kaplan-Meier Plot of Duration of Response
Clinical Lymphoma, Myeloma & Leukemia November 2016Patients with cutaneous tumors represent a subpopulation of
CTCL with inferior outcomes.2,3 The presence of cutaneous tumors
is an independent prognostic factor for poorer overall survival,
disease-dependent survival, and risk of disease progression, with the
Figure 2 Common (> 10%) Treatment-Emergent Adverse Events (AEs)
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642 -prognostic signiﬁcance of the risk of disease progression dependent
on the tumor distribution (eg, solitary, localized, regional, general-
ized).2 Patients with cutaneous tumors have a median survival of 4.1
years compared with 17.7 to 38.3 years for lower stages of skin
involvement and 24.4 years for MF/SS overall (all stages).2,3 The
results of the present study demonstrate that romidepsin is effective
in this population, with a 45% ORR and median DOR not reached.
Cutaneous toxicity has been reported in patients with T-cell
lymphoma and signiﬁcant skin involvement and can lead to infec-
tion, treatment discontinuation, and death. A phase II study of
panobinostat was terminated because of severe infections associated
with skin tumor shrinkage in patients with adult T-cell leukemia/
lymphoma.23,24 Additionally, severe skin erosions leading to treat-
ment discontinuation and fatal septic shock have been reported in
patients with adult T-cell leukemia/lymphoma treated with prala-
trexate and cytotoxic chemotherapy.25,26 In a retrospective study of
pralatrexate in 22 patients with CTCL or PTCL, 14 of 18 patients
with CTCL (78%) who had received pralatrexate developed cuta-
neous toxicity, resulting in infection and treatment discontinuation
in some patients. One patient with PTCL developed cutaneous
toxicity that resulted in death.27 In the present study, no patients
with cutaneous tumors who were treated with romidepsin experi-
enced cutaneous toxicity. Only 1 patient withdrew from treatment
because of an AE (fatigue), and most withdrawals from treatment
were because of PD.
The development of cutaneous toxicity in patients with T-cell
lymphoma and signiﬁcant skin involvement during treatment
response is believed to be caused by the rapid lysis of tumor cells in
the skin and has been suggested to be akin to the conventional
tumor lysis syndrome typically observed during treatment with
chemotherapy.25,26 With chemotherapy agents, toxicity often
occurs after administration of the ﬁrst dose.25-27 However, treat-
ment with romidepsin in the present study resulted in a median
TTR of 1.9 months in patients with cutaneous tumors without
cutaneous toxicity.
Skin-directed therapies used in treating early-stage MF are often
inadequate for patients with FMF, necessitating treatment with
systemic agents or radiation.6,14,28 No standardized treatment
paradigm is available for patients with CTCL, and relatively few
data are available regarding systemic treatments speciﬁcally focused
on FMF.6,14 Previous retrospective studies of patients with FMF
have reported on treatment outcomes for small numbers of indi-
vidual patients.12-14,28,29 In the present study, most patients with
folliculotropic involvement responded to romidepsin, and 90%
achieved SD or better. Although the median DOR for those with a
treatment response was 3.6 months, a measure of the potential
durability is difﬁcult owing to the small patient numbers and
because the patient with the longest response discontinued treat-
ment while in response at the end of the planned 6 cycles.
In the overall population of the pivotal phase II study, which was
the basis of the present analysis, 60 of 65 patients (92%) who re-
ported moderate to severe pruritus at baseline achieved a reduction
in itch.20,21 In the present retrospective analysis of the pivotal study,
patients with cutaneous tumors and/or folliculotropic involvement
achieved reductions in pruritus similar to those of the overall
treatment population. Similar reductions in pruritus were reported
with the oral histone deacetylase inhibitor vorinostat in patientsClinical Lymphoma, Myeloma & Leukemia November 2016with relapsed or refractory CTCL; however, concomitant antipru-
ritic treatments were allowed.30 A reduction in pruritus has been a
signiﬁcant patient-related endpoint in the treatment of CTCL,
because intractable pruritus is frequently the most difﬁcult aspect of
the disease to control.
Conclusion
Patients with cutaneous tumors and/or folliculotropic involve-
ment represent 2 CTCL subpopulations associated with poorer
outcomes and a greater risk of disease progression. In both cases,
systemic therapies are often used after disease progression with skin-
directed therapies. Agents with favorable efﬁcacy and safety proﬁles,
such as romidepsin, provide additional therapeutic options for
patients with these difﬁcult and disabling subsets of CTCL.
Clinical Practice Points
 Cutaneous tumors and/or folliculotropic involvement are nega-
tive prognostic factors for patients with CTCL.
 The histone deacetylase inhibitor romidepsin induced a clinical
response or stable disease in most patients with cutaneous tumors
and/or folliculotropic disease involvement.
 Patients with cutaneous tumors and/or folliculotropic involve-
ment treated with romidepsin experienced marked reductions in
pruritus.
 Although treatment-associated cutaneous toxicity is a potential
concern for patients with T-cell lymphoma and signiﬁcant skin
involvement, no cutaneous toxicity in patients with cutaneous
tumors treated with romidepsin was reported.
 Data support the use of romidepsin in patients with cutaneous
tumors and/or folliculotropic disease involvement.Acknowledgments
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